Aplindore

From Self-sufficiency
Jump to: navigation, search
Aplindore
File:Aplindore.png
Systematic (IUPAC) name
(2S)-2-[(phenylmethylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[3,2-e]indol-8-one
Identifiers
CAS Number 189681-71-8
ATC code none
PubChem CID 6440763
Chemical data
Formula C18H18N2O3
Molar mass 310.346 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2.[1] It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



pt:Aplindore
  1. Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. European Journal of Pharmacology. 2006 Dec 15;552(1-3):36-45. PMID 17056032
  2. Neurogen licenses Aplindore from Wyeth (dead link)